Answer

No, you should exercise extreme caution and avoid combining Dong Quai with GI prokinetics (specifically cisapride) without strict medical supervision. This combination carries a critical risk of increasing drug plasma levels, which may lead to toxicity.

Evidence Assessment

Quality Score: 35 (Tier D - Preliminary/Weak Evidence) The assessment of this interaction is based on pharmacological inference (CYP450 enzyme inhibition) rather than randomized controlled trials or clinical case reports. While the biochemical mechanism is plausible, clinical data specifically documenting this pair is limited.

Clinical Evidence

The interaction is driven by the metabolic pathway of the drug. Dong Quai acts as a weak inhibitor of the cytochrome P450 enzyme CYP3A4. Many GI prokinetics, most notably cisapride, are primary substrates of CYP3A4.

When CYP3A4 is inhibited, the body's ability to metabolize and clear the prokinetic agent is reduced. This leads to an increase in the plasma concentration of the drug, which significantly elevates the risk of dose-dependent adverse effects. In the case of cisapride, elevated levels are associated with severe cardiac risks, including QT interval prolongation and potentially fatal arrhythmias.

Practical Guidance

• Populations at Risk: Individuals with pre-existing cardiac conditions or those taking other medications that prolong the QT interval are at the highest risk.
• Monitoring: If this combination is used, clinicians must monitor for signs of toxicity, such as palpitations, dizziness, or fainting.
• Management: A dose reduction of the prokinetic agent may be necessary, or an alternative supplement that does not inhibit CYP3A4 should be selected.

Safety & Interactions

Contraindication: CRITICAL / CAUTION

• Drug Class: Prokinetic agents (e.g., Cisapride).
• Mechanism: Inhibition of CYP3A4 metabolism, leading to increased drug plasma concentrations.
• Clinical Management: Avoid concurrent use if possible. If used, closely monitor for increased adverse effects of the prokinetic.
• High-Risk Populations:
  • Cardiac Patients: High risk of arrhythmia.
  • Elderly: Reduced baseline renal/hepatic clearance may exacerbate the interaction.
  • Polypharmacy: Patients taking other CYP3A4 inhibitors (e.g., certain antifungals or antibiotics) face a compounded risk of toxicity.

Consult a healthcare provider before combining these substances.